13th July, 2024

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

**Scrip Code: 500087**

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

**Sub: USFDA inspection at Company's manufacturing facility in Kurkumbh, Maharashtra, India**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 8th May, 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at our Kurkumbh manufacturing facility, we wish to inform you that the United States Food and Drug Administration (USFDA) vide communication dated Friday, 12th July, 2024 (10.18 PM IST) has classified the above referred inspection as Voluntary Action Indicated ("VAI").

Please take the above information on record.

Yours faithfully,
**For Cipla Limited**

RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2024.07.13 11:06:38 +05'30'

**Rajendra Chopra**
**Company Secretary**

Prepared by: Mandar Kurghode